Opaganib shows promise in preventing ARDS-induced thrombosis
Opaganib reduced blood clot length and weight in a pre-clinical model of Acute Respiratory Distress Syndrome (ARDS).
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Opaganib reduced blood clot length and weight in a pre-clinical model of Acute Respiratory Distress Syndrome (ARDS).
Scientists have created a drug discovery platform that enables the discovery and optimisation of RNA-targeting compounds.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
New research has provided a metabolic atlas for insights into obesity and tumours' ability to hide from the immune system.
Scientists shows targeting cholesterol or phosphatidylinositol phosphate (PIP) could be a promising strategy to combat multiple coronaviruses.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
In a new report, Elsevier describes how it used text mining to reveal the top trends in pancreatic cancer research – this article outlines the findings.
Elevated levels of a biomarker related to blood vessel damage have been found in all children with SARS-CoV-2 infection.
Researchers have shown how increased YTHDF3 expression correlates with brain cancer metastases, making it a target for the condition.
Mice treated with a small molecule inhibitor of cadherin 11 (CDH11) had reduced pancreatic cancer growth and increased survival time.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
Researchers have developed a novel insulin molecule that responds to glucose levels in the blood sugar of rats, which they say could help patients with type 1 diabetes.